Gout causes extremely painful episodes of acute inflammatory arthritis, joint damage and chronic tophaceous disease ... controlled trials to guide treatment, attention to these factors, including ...

Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

which lower the urate in the blood and prevent urate crystal forming in the joints (or dissolve them if they are already there). Gout is a chronic disease, so treatment is lifelong.

It has been awarded a fast-track review by the FDA, which Sobi said “underscores the urgent need for new treatment options for patients with chronic refractory gout.” If approved, it will ...

A major international study has found gout is a chronic illness where genetics is a major cause, rather than lifestyle choices of the sufferer.